Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. surgery radiation
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Surgery Radiation Articles & Analysis

38 news found

Bayer expands global clinical program for darolutamide in prostate cancer

Bayer expands global clinical program for darolutamide in prostate cancer

BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well as metastatic ...

ByBayer AG


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.7 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.80F[i] At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis

How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis

For many young men, the prognosis is often dire, and the progression is more aggressive than in older peers at a similar stage and grade. PC treatments include surgery and radiation therapy, bringing added risks of urinary incontinence and erectile dysfunction. ...

ByLifespin GmbH


CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.6 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

Standard treatment options for RCC are surgery, radiation, chemotherapy, targeted therapy or immunotherapy. ...

ByGeneCentric Therapeutics, Inc.


Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial

Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial

The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. It is being conducted at three leading canine oncology centers – the Flint Animal Cancer Center at Colorado State University, the School of Veterinary Medicine at University of Wisconsin-Madison and the University of ...

ByCalviri


PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting

PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting

The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET. ...

ByPreludeDx


PreludeDx to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT During Oral Presentation at ASCO 2022 Annual Meeting

PreludeDx to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT During Oral Presentation at ASCO 2022 Annual Meeting

The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...

ByPreludeDx


PreludeDx Presents Compelling DCISionRT Study Results in Young and High-Grade DCIS Patients at ASBrS 2022 Annual Meeting

PreludeDx Presents Compelling DCISionRT Study Results in Young and High-Grade DCIS Patients at ASBrS 2022 Annual Meeting

The study validated the clinical utility of DCISionRT with its Residual Risk Subtype (RRT) to predict recurrence risk and radiation therapy benefit in patients under fifty years old and/or high-grade DCIS. ...

ByPreludeDx


PreludeDx Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio

PreludeDx Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio

” About DCISionRT for Breast DCIS DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...

ByPreludeDx


PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

The study included 493 patients from three cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT). DCISionRT and its RRt classified patients into Low, Elevated and Residual Risk groups with the Residual Risk group having the highest 10-year ipsilateral breast recurrence (IBR) risk without RT and significantly elevated IBR ...

ByPreludeDx


Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

Lustig, M.D., Professor of Clinical Radiation Oncology and Director of Clinical Operations, Radiation Oncology at Penn Medicine; Chad Tang, M.D., Assistant Professor, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center; Cullen M. ...

ByCervoMed


Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

In addition, a study to explore the potential of darolutamide in the early setting for patients who have been treated with surgery or radiation and now see a rise in their prostate specific antigen (PSA) levels is also planned. ...

ByBayer AG


Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System

Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System

With The ViZOR, surgeons can see inside a patient’s anatomy through skin and tissue, for easier, faster and safer surgeries. The ViZOR can be used in many procedures, with the first intended use in minimally invasive spine surgeries. ...

ByAugmedics


New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

When looking at key risk factors for BCRL, including body weight, stage of cancer, type of cancer surgery, lymph node dissection, chemotherapy, and radiation, the benefit of using L-Dex monitoring was consistent and showed the utility of L-Dex across a large group of breast cancer ...

ByImpediMed Inc.


Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems

Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems

Food and Drug Administration 510(k) cleared imaging system that features the unique ability to instantly capture 3D images with very low-dose radiation. This approach makes the 3D images available throughout surgery, enabling real time visualization. ...

BynView medical Inc.


GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

They are implanted by the surgeon and deliver ninety percent of the radiation dose in 33 days. After 100 days, the GammaTile radiation sources are exhausted, and the collagen tiles disintegrate. ...

ByGT Medical Technologies, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT